JPRN-UMIN000026648已完成2 期
Adjuvant Treatment with nivolumab in the Prevention of recurrence after curative treatment of Hepatocellular Carcinoma(NIVOLVE) - NIVOLVE
Kindai University Faculty of Medicine Department of Gastroenterology and Hepatology0 个研究点目标入组 55 人开始时间: 2017年3月23日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.History of treatment except for hepatic resection of RFA 2.History or present of autoimmune disease 3.History or present of inestitial neumonia 4.History of malignancy 5.Renal falure 6.severe heart disease 7.severe hypertension 8.active infection 9.History of treatment using immunotherapy such as immune checkpoint inhibitor, peptide vaccine, biochemical modulator and Lymphocyte stimulation therapy 10.pregnancy or breast feeding
研究者
相似试验
进行中（未招募）
1 期
Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratification (NivoMela)CTIS2023-509394-23-00niversitaetsklinikum Essen AöR423
进行中（未招募）
1 期
A study to test efficacy and safety of nivolumab-treatment in stage II melanoma patients with a high risk of relapseEUCTR2019-002276-13-DEniversity Hospital Essen, Department of Dermatology374
进行中（未招募）
1 期
A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinomaThoracic esophageal cancerJPRN-jRCT2031180172Kato Ken36
进行中（未招募）
1 期
EOpredict-Lung is a clinical study in subjects with histologically or cytologically confirmed, early stage or locally advanced non-small cell lung cancer (NSCLC) eligible for curative resection. This study will determine the feasibility of two cycles of preoperative immunotherapy with nivolumab or as combination nivolumab plus relatlimab.non-small cell lung cancer (NSCLC) of clinical stages IB, II and selected stage III AMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002478-29-DEniversity Hospital Essen60
招募中
2 期
Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung)2024-513074-22-00Universitaetsklinikum Essen AöR, Universitaetsklinikum Essen AöR90